source
- STAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsThe FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.STAT · 3h ago↗ source
- Milestone Pharmaceuticals trims 20% workforce after FDA approval as Q3 sales reach $1 millionMilestone Pharmaceuticals announced it is reducing its headcount by about one‑fifth following the recent FDA approval of its heart‑arrhythmia therapy. The cut affects roughly 20% of the company’s s…